TY -的T1 -大剂量糖皮质激素是有益的ial in COVID-19? Response to Correspondence JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00324-2021 SP - 2100324 AU - Edalatifard, Maryam AU - Akhtari, Maryam AU - Salehi, Mohammadreza AU - Farhadi, Elham AU - Jamshidi, Ahmadreza AU - Mahmoudi, Mahdi AU - Rostamian, Abdolrahman Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/02/11/13993003.00324-2021.abstract N2 - In the recent correspondence “Is high-dose glucocorticoid beneficial in COVID-19?” Muthu et al. raised some issues related to our recent clinical trial “Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial” [1]. This provides a welcome opportunity to further explain the outcome of using a high dose of glucocorticoid for the treatment of severe COVID-19 patients.Our clinical trial supports the beneficial use of a high dose of methylprednisolone for the ‎treatment of severe COVID-19 patients.‎ ER -